Skip to content
AiSeekAiSeek
Sign in

Company

Biohaven

FollowOpen structure mapAsk about thisResearch this company

Description

Headquarters
US

Structure of Biohaven

Biohaven

Company

7 connections
UpstreamSupply and dependency3 of 5
PeersCompetition and partners
OwnProducts and technology
Relationship began2026
BiohavenCompany · 7 connections
Layer 1

UpstreamSupply and dependency3

PeersCompetition and partners2

OwnProducts and technology2

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Biohavenagreement with →Ono Pharma
    Company · Ono PharmaEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320
      View source
  • BHV-1310part of →Biohaven
    Product · BHV-1310Evidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      extending the breadth and durability of Biohaven's MoDE IgG degrader portfolio
      View source
  • BHV-1320part of →Biohaven
    Product · BHV-1320Evidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      extending the breadth and durability of Biohaven's MoDE IgG degrader portfolio
      View source
  • Biohavenuses →MoDE
    Technology · MoDEEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven's MoDE platform is the first clinically validated technology enabling the targeted degradation of disease-causing proteins in the extracellular space.
      View source
  • Biohavenuses →TRAP
    Technology · TRAPEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven's next-generation TRAP (Targeted Removal of Aberrant Protein) degraders extend the platform with highly selective molecules, each engineered to remove a single specific disease-causing protein.
      View source
  • Biohavenoperates in →immunology
    Industry · immunologyEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.
      View source
  • Biohavenoperates in →neuroscience
    Industry · neuroscienceEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.
      View source
  • Biohavenoperates in →oncology
    Industry · oncologyEvidence 1
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.
      View source

Showing 1 to 8 of 13

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
operates inneuroscience

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.
    View source
FactEvidence 1
operates inoncology

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments across immunology, neuroscience, and oncology.
    View source
FactEvidence 1
usesKv7 ion channel modulation

Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…
    View source
FactEvidence 1
usesantibody-drug conjugates

Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…
    View source
FactEvidence 1
usesmyostatin inhibition

Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven is advancing an innovative portfolio of therapeutics built on proven drug development experience and multiple proprietary platforms, including Kv7 ion channel modulation for epilepsy; MoDE and TRAP extracellular protein degradation for immunological diseases; next gener…
    View source
FactEvidence 1
usesTRAP

Biohaven's next-generation TRAP (Targeted Removal of Aberrant Protein) degraders extend the platform with highly selective molecules, each engineered to remove a single specific disease-causing protein.

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Biohaven's next-generation TRAP (Targeted Removal of Aberrant Protein) degraders extend the platform with highly selective molecules, each engineered to remove a single specific disease-causing protein.
    View source

Showing 1 to 6 of 18

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Not available: Company signals · Financials · Filings · Guidance